Article

June 27-July 1: Who said What in Biotech and Pharmaceutical Industries?

219 views

These are some fresh promises that researchers and scientists made regarding their innovation and research and the collaborators filled us with the hope to take their business to a higher level and benefit the human race;

Quote 1.

I am very proud of this achievement that rewards our resilience and pioneering approach in developing a highly innovative advanced therapy. The opinion from CHMP represents a major milestone in demonstrating our ability to translate a scientific discovery into an effective treatment for patients. Indeed, MolMed is the first example of a biotech company able to manage entirely in-house the whole cycle of discovery, development, and manufacturing of ex-vivo cell and gene therapy products-Who said it? Answer is here

Quote 2.

Biocon is committed to develop innovative therapies that address unmet medical needs and the initiation of the Phase II/III study investigating QPI-1007 in NAION in India is an important step towards this goal. India has a significant NAION patient population and we are pleased to be the first biopharma company in the country to provide an siRNA-based therapy that is likely to benefit thousands of patients who either have no access to treatment or cannot afford it-Who said it? Answer is here

Quote 3.

The observed protection in macaques indicates the significant potential for the TDF-FTC drug combination delivered via the pod-IVR to successfully prevent sexual HIV infection in humans-Who said it? Answer is here

Quote 4.

Medivation’s scarcity value is high–and Sanofi aims to seize the company at an opportunistic, inferior price by replacing your highly qualified Board with a slate of hand-picked nominees with minimal biotechnology industry experience-Who said it? Answer is here

Quote 5.

Double-strand breaks are the most detrimental type of DNA damage and are caused by genotoxins, reactive oxygen species, and ionizing radiation. The repair mechanism for double-stranded breaks is highly error prone, and such errors can lead to cancer’s development-Who said it? Answer is here

Quote 6.

These data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures in this highly treatment-resistant population together with an acceptable safety and tolerability profile, which is consistent with my previous clinical experience with Epidiolex. I am excited about the prospect of Epidiolex being made available on prescription in the future and believe it has the potential to make an important difference to the lives of many patients-Who said it? Answer is here

Quote 7.

Urothelial cancer is a common type of bladder cancer where patients experience high rates of recurrence and remains an area where new treatment approaches are needed, further underscoring the importance of this designation for Opdivo-Who said it? Answer is here

Quote 8.

Panacea Biotec has always endeavored to partner with medical practitioners in assisting to manage their patients better by introducing new innovative and good quality products”-Who said it? Answer is here

Quote 9.

OCREVUS is the first investigational medicine to significantly reduce disability progression in people with relapsing and primary progressive forms of MS”-Who said it? Answer is here

Quote 10.

This opportunity to work with and learn from a world leader in the late-stage development and commercialization of immune-oncology drugs gives us the opportunity to take our lead drugs through clinical development and into commercialization in the U.S. and, with the other molecules to be developed, continues to expand the reach of our technology-Who said it? Answer is here

Quote 11.

We believe we have achieved our goal of optimizing the benefit/risk profile for the patients and look forward to the presentation of the full data set from this study at the European Society for Medical Oncology (ESMO) congress in October-Who said it? Answer is here

Quote 12.

 “Approval represents a significant advance for patients with HCV genotypes 2 and 3, who previously required more complex and costly regimens.As the first and only pan-genotypic cure for hepatitis C, Epclusa has the potential to eliminate the need for genotype testing, which can be a barrier to treatment in certain resource-constrained settings. We look forward to making Epclusa available to patients around the world as quickly as possible-Who said it? Answer is here

Quote 13.

We are committed to continuing to evaluate the potential benefit ibrutinib may offer in treating blood cancers, solid tumors and other health conditions with unmet medical needs-Who said it? Answer is here

 

 

Leave a reply

Your email address will not be published. Required fields are marked *